IRADIMED CORP (IRMD)

As of 31 August 2026, short interest in IRMD is 697,251 shares, up 27,068 shares over the last month. Over the last 48 readings it ranged from 68,279 shares (13 September 2024) to 727,749 shares (14 August 2026). The latest reading sits at the top of that range. At the reported average volume of 83K shares a day that is 8.4 days to cover, elevated.

<iframe src="https://xoomar.com/embed/stocks/irmd" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 17 September 2026, the short share of IRMD volume is 54.8%, up 20.4 points over the last five sessions. Over the last 52 readings it ranged from 16.7% (11 September 2026) to 74.3% (10 July 2026). The latest reading is 11.8 points above the 30-session average of 43.0%, on 31K shares reported.

As of 25 August 2026, the fails-to-deliver balance in IRMD is 47 shares, down 1,650 shares over the last settlement date. Over the last 52 readings it ranged from 3 shares (28 April 2025) to 13,346 shares (1 July 2026). The latest reading sits at the bottom of that range.

Insiders at IRMD reported 2 open-market sells worth $123K in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: ALLEN MONTY K on 2026-09-03.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

7 Form 144 notices on file for IRMD worth $20.0M at the prices reported; 0 in the last 90 days worth $0. Latest: Roger E. Susi filed on 2026-03-06 to sell 100,000 shares ($9.9M) from 2026-03-06.

4 holders above 5% have filed on IRMD, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 5.0% of the class (641,128 shares), filed 2026-07-28 for an event on 2026-06-30.

5 of the 30 tracked managers held IRMD at their latest 13F, $58.9M in total at quarter-end prices. Renaissance Technologies is the largest at $37.7M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) IRADIMED CORP reported revenue of $20.5M, up 0.3% from the same quarter a year earlier, and net income of $5.2M (0.41 diluted EPS). In FY 2025 it generated $24.9M of operating cash flow and spent $15.0M on dividends.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.